Frank St Michael

Title: Frank St Michael: Innovator in Vaccine Development

Introduction

Frank St Michael is a notable inventor based in Ottawa, Canada. He has made significant contributions to the field of vaccine development through his innovative research. His work focuses on the enzymatic degradation of lipid A fatty acids of bacterial lipopolysaccharides (LPS), which has implications for combating gram-negative bacteria.

Latest Patents

Frank St Michael holds a patent for his invention titled "Enzymatic degradation of lipid A fatty acids of bacterial LPS." This patent describes novel enzymes, processes, and antigenic structures that are useful in producing vaccines and compounds aimed at fighting gram-negative bacteria. The enzymes he isolated from slime molds are specifically designed to degrade lipopolysaccharide (LPS). This enzymatic degradation allows for the preservation of immunogenic epitopes of the core oligosaccharide portion of the LPS, ensuring that these critical components remain unmodified during the removal of fatty acids from the lipid A region of the LPS molecule.

Career Highlights

Frank St Michael is affiliated with the National Research Council of Canada, where he continues to advance his research in the field of microbiology and vaccine development. His work has garnered attention for its potential to improve vaccine efficacy and safety.

Collaborations

Frank has collaborated with notable colleagues, including Andrew Cox and Dhamodharan Neelamegan, who have contributed to his research endeavors.

Conclusion

Frank St Michael's innovative work in enzymatic degradation and vaccine development highlights his role as a key inventor in the field. His contributions are paving the way for advancements in combating bacterial infections and improving public health.